RE-CELLULARIZATION VIA ELECTROPORATION THERAPY (RECET) COMBINED WITH GLP-1RA TO REPLACE INSULIN THERAPY IN PATIENTS WITH TYPE 2 DIABETES 6 MONTHS RESULTS OF THE EMINENT STUDY

被引：0
|
作者：
Busch, Celine [1 ]
Meiring, Suzanne [1 ]
Van Baar, Annieke [1 ]
Holleman, Frits [1 ]
Nieuwdorp, Max [1 ]
Bergman, Jacques [1 ]
机构：
[1] Amsterdam UMC Locatie AMC, Amsterdam, Netherlands
来源：
GASTROINTESTINAL ENDOSCOPY | 2023年 / 97卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1272
引用
收藏
页码：AB760 / AB760
页数：1
相关论文
共 50 条
  • [41] Risk of Cardiovascular Outcomes in Diabetes Patients following the Addition of SGLT2 Inhibitors vs. Sulfonylureas to Baseline GLP-1RA Therapy
    Dave, Chintan
    Kim, Seoyoung C.
    Goldfine, Allison
    Glynn, Robert
    Patorno, Elisabetta
    DIABETES, 2020, 69
  • [42] In insulin-naive patients with Type 2 diabetes inadequately controlled on a glucagon-like peptide-1 receptor agonist (GLP-1RA), IDegLira (combination of insulin degludec and liraglutide) resulted in improved patient-reported outcomes vs unchanged GLP-1RA
    Russell-Jones, D.
    Brod, M.
    Linjawi, S.
    Bode, B. W.
    Chaykin, L. B.
    Courreges, J. P.
    Handelsman, Y.
    Kongso, J. H.
    Reiter, P. D.
    Simpson, R. W.
    DIABETIC MEDICINE, 2016, 33 : 68 - 68
  • [43] Combined therapy with SGLT2i and GLP-1ra improves cardiovascular prognosis in a population with diabetes and overweigh or obesity. A real-world clinical practice study
    Garcia Vega, D.
    Cinza-Sanjurjo, S.
    Gonzalez-Juanatey, J. R.
    Eiras, S.
    EUROPEAN HEART JOURNAL, 2023, 44
  • [44] Clinical outcomes after 24 months of insulin therapy in patients with type 2 diabetes in five countries: results from the TREAT study
    Oguz, A.
    Benroubi, M.
    Brismar, K.
    Melo, P.
    Morar, C.
    Cleall, S. P.
    Giaconia, J.
    Schmitt, H.
    CURRENT MEDICAL RESEARCH AND OPINION, 2013, 29 (08) : 911 - 920
  • [45] Real-World Outcomes of Addition of Insulin Glargine 300 U/mL (Gla-300) to GLP-1RA Therapy in People with Type 2 Diabetes (PWD2): The DELIVER-G Study
    Bailey, Timothy S.
    Westerbacka, Jukka
    Nicholls, Charlie
    Gill, Jasvinder
    Jones, Merwyn
    Shenoy, Laxmi
    DIABETES, 2021, 70
  • [46] Effect of adding GLP-1RA on mortality, cardiovascular events, and metabolic outcomes among insulin-treated patients with type 2 diabetes: A large retrospective UK cohort study
    Anyanwagu, Uchenna
    Mamza, Jil
    Donnelly, Richard
    Idris, Iskandar
    AMERICAN HEART JOURNAL, 2018, 196 : 18 - 27
  • [47] Insulin titration gaining an understanding of the burden of Type 2 diabetes in Europe (INSTIGATE study): costs associated with the first 6 months of insulin therapy in-patients with Type 2 diabetes in UK
    Kilcoyne, A.
    Jones, S.
    Nicolay, C.
    Smith, H.
    DIABETIC MEDICINE, 2008, 25
  • [48] Hypoglycaemia in patients with type 1 and type 2 diabetes mellitus on insulin therapy. Results of the global HAT study in Argentina
    Costa Gil, Jose E.
    Linari, Maria A.
    Pugnaloni, Natalia
    Zambon, Fabio G.
    Perez Manghi, Federico
    Rezzonico, Mariana
    MEDICINA-BUENOS AIRES, 2017, 77 (06) : 449 - 457
  • [49] Using CVD risk scores to select between GLP-1RA or SGLT2i therapy in type 2 diabetes: modelling the combined effects on both major atherosclerotic and heart failure events
    Sacre, J. W.
    Magliano, D. J.
    Shaw, J. E.
    DIABETOLOGIA, 2022, 65 (SUPPL 1) : S418 - S419
  • [50] Risk of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Addition of SGLT2 Inhibitors Versus Sulfonylureas to Baseline GLP-1RA Therapy (vol 143, pg 770, 2021)
    Dave
    CIRCULATION, 2021, 143 (08) : e744 - e744
12345